ABN.AS: $40.38 ▲ 0.17 (0.42%)BMPS.MI: $11.57 ▼ -0.15 (-1.30%)BNZL.L: $2,754.00 ▼ -2.00 (-0.07%)DSFIR.AS: $90.76 ▲ 0.88 (0.98%)NESTE.HE: $32.85 ▲ 0.20 (0.61%)REP.MC: $27.99 ▼ -0.15 (-0.53%)SGRO.L: $957.40 ▲ 0.40 (0.04%)CIEN: $395.79 ▲ 3.31 (0.84%)DDOG: $235.62 ▲ 3.07 (1.32%)DELL: $441.98 ▲ 7.20 (1.66%)FTNT: $153.51 ▲ 2.72 (1.80%)HPE: $53.44 ▲ 0.55 (1.04%)MPC: $360.72 ▲ 2.49 (0.70%)PANW: $357.87 ▲ 8.31 (2.38%)CMG: $36.90 ▲ 1.61 (4.56%)DASH: $223.49 ▲ 1.13 (0.51%)MSFT: $483.24 ▲ 2.09 (0.43%)REGN: $834.04 ▲ 7.40 (0.90%)RTX: $209.91 ▼ -2.38 (-1.12%)VLO: $348.86 ▲ 7.35 (2.15%)MU: $966.78 ▼ -7.55 (-0.77%)STX: $850.00 ▼ -0.24 (-0.03%)WDC: $459.44 ▼ -9.61 (-2.05%)AAPL: $309.35 ▼ -1.95 (-0.63%)AMZN: $258.63 ▼ -1.48 (-0.57%)NVDA: $214.72 ▼ -2.13 (-0.98%)ABNB: $187.30 ▲ 2.30 (1.24%)CRWD: $191.95 ▲ 1.61 (0.85%)ACN: $185.28 ▲ 3.93 (2.17%)FCX: $76.67 ▲ 5.45 (7.65%)INTU: $367.00 ▲ 5.13 (1.42%)NEM: $131.58 ▲ 3.94 (3.09%)PLTR: $179.94 ▲ 5.98 (3.44%)ADYEN.AS: $1,074.00 ▲ 11.20 (1.05%)ARGX.BR: $902.00 ▲ 16.80 (1.90%)KRX.IR: $100.60 ▼ -0.10 (-0.10%)SAP.DE: $188.12 ▲ 2.48 (1.34%)VWS.CO: $208.30 ▼ -4.20 (-1.98%)

Company Details

AVROBIO, Inc.

AVRO - NASDAQ

Identifiants & Marche

Ticker AVRO
ISIN US05455M1009
CIK 0001681087
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Voir l'evolution du cours Retour